Condition
Overweight and Obesity Clinical Trials
Studies of overweight and obesity, matched by condition name and medical subject headings. Start with those open to enrolment.
In numbers
Open to volunteers: recruiting, not yet recruiting or enrolling by invitation. Active adds studies under way that have stopped recruiting.
Open to volunteers
All 748Obesity, Obesity & Overweight
Real-world Exploration of Digital iNnovation in the Management of Excess Weight
This is a real-world study. The purpose of this research is to explore whether a new National Institute for Health and Care Excellence (NICE)-approved digital weight-management model of care can improve health service delivery…
- Trial name
- RENEW (NCT07283978)
- Testing
- Digital Weight Management Programme
- Where
- United Kingdom
- Volunteers
- 580 people
- Sponsor
- Guy's and St Thomas' NHS Foundation Trust
Obese, Overweight
A Study of SA030 Injection in Overweight or Obese Participants
This study is the first time SA030 is being given to people. The goal is to understand how safe it is, how well it is tolerated, and how the body processes and responds to a single dose of SA030 in individuals who are overweight…
- Trial name
- NCT07479862
- Testing
- SA030 Injection
- Where
- 2 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Suzhou Siran Biotechnology Co.,Ltd.
Overweight or Obesity
A Single Ascending Dose and Multiple Ascending Doses Study of SYH2082 Injection in Healthy Participants
To evaluate the safety and tolerability of single dose and multiple doses of SYH2082 Injection in healthy participants.
- Trial name
- NCT07532655
- Testing
- SYH2082 Injection
- Where
- Australia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Obesity or Overweight
Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)
Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.
- Trial name
- NCT07575399
- Testing
- Maridebart Cafraglutide
- Where
- 54 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Amgen
Type 1 Diabetes, Overweight , Obesity
Lean Mass Changes With Semaglutide in Adults With Type 1 Diabetes and Overweight/Obesity.
The goal of this 24 week double-blinded, randomized, parallel controlled clinical trial is to learn how semaglutide affects body composition in adults with type 1 diabetes and overweight/obesity.
- Trial name
- SEMA-T1D-BODY (NCT07891156)
- Testing
- Semaglutide
- Where
- Canada
- Volunteers
- 40 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Physical Inactivity, Overweight
Individual Variability in Energy Compensation After a 12-Week Supervised Exercise Intervention
This prospective, single-arm interventional study will investigate why adults receiving the same prescribed dose and relative intensity of exercise show divergent changes in energy balance, body weight, and body composition.
- Conditions
- Physical Inactivity, Overweight, Obesity
- Trial name
- NCT07893249
- Testing
- Supervised Aerobic Exercise Programme
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Obesity, Overweight
Improving Glycemic Control With Electrical Stimulation
Once written consent is obtained, the participant will be provided with an accelerometer to be worn for 7 days to assess current physical activity levels.
- Conditions
- Obesity, Overweight, Insulin Resistance
- Trial name
- NCT03947697
- Testing
- Neuromuscular Electrical Stimulation (Sensory), Neuromuscular Electrical Stimulation, Resistance Training
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- University of Texas, El Paso
Pre Diabetic, Obesity & Overweight
The Impact of Continuous Glucose Monitoring on Glucose Variability and Weight Loss in Individuals With Prediabetes and Obesity
This randomized, crossover interventional study evaluates the effects of real-time (open) versus blinded continuous glucose monitoring (CGM) on glycemic variability, lifestyle behaviors, and metabolic outcomes in adults with…
- Trial name
- CGM (NCT07423065)
- Testing
- Continuous Glucose Monitoring (CGM)
- Where
- 3 sites in Slovenia
- Volunteers
- 34 people
- Sponsor
- University of Primorska
Obesity & Overweight, Childhood
Project GAME ON! A Digital Comic Tool to Promote Healthy Behaviors
This clinical trial aims to evaluate an interactive, culturally relevant digital health promotion comic designed to support healthy dietary and physical activity behaviors among Black/African American and Latino children ages 8…
- Conditions
- Obesity & Overweight, Childhood, Diet Habits, Engagement
- Trial name
- NCT07820735
- Testing
- Web-based customizable comic and newsletters, Didactic health information and newsletters, Web-based comic and newsletters
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Tufts University
Obesity, Overweight
A Study to Investigate the Effect of LY4086940 Versus Placebo in Participants With Obesity or Overweight and Without Type 2 Diabetes
The purpose of this study, performed under the master protocol W8M-MC- CWMM (NCT06143956), is to evaluate the efficacy and safety of LY4086940 compared with placebo in participants without type 2 diabetes who have obesity or who…
- Trial name
- NCT07890376
- Testing
- LY4086940
- Where
- 46 sites in United States, Argentina
- Volunteers
- 460 people
- Sponsor
- Eli Lilly and Company
Completed, with results posted
All –Obesity, Lifestyle-related Condition
Lifestyle Intervention in Preparation for Pregnancy (LIPP)
Studies evaluating lifestyle intervention in obese women during pregnancy have reported limited success in decreasing excessive gestational weight gain, and have failed to achieve the key outcome of breaking the obesity cycle and…
- Conditions
- Obesity, Lifestyle-related Condition, Macrosomia, Fetal
- Trial name
- NCT03146156
- Testing
- Lifestyle Intervention
- Where
- 4 sites in United States
- Volunteers
- 143 people, healthy volunteers welcome
- Sponsor
- Tufts Medical Center
Overweight, Obesity
Sharing Digital Self-Monitoring Data With Others to Enhance Long-Term Weight Loss
Adults attempting weight loss through lifestyle modification (LM) typically find maintenance of behavior change difficult. Outcomes might be improved if participants are provided with sustained sources of accountability and…
- Trial name
- FitLink (NCT05180448)
- Testing
- Coach Share On, Group Share On, Friend/Family Share On
- Where
- United States
- Volunteers
- 321 people, healthy volunteers welcome
- Sponsor
- Drexel University
Overweight and Obesity
Circadian Timing, Information Processing and Energy Balance Study
This study design will test biological and behavioral mechanisms in the cross-sectional analyses and determine the prospective effects of circadian alignment and sleep on changes in cardiometabolic risk factors.
- Trial name
- TIME (NCT04759755)
- Where
- United States
- Volunteers
- 139 people, healthy volunteers welcome
- Sponsor
- University of Utah
Metabolic Syndrome, Hypertension
Aldosterone, the Mineralocorticoid Receptor, and Cardiovascular Disease in Obesity
This study will evaluate whether the mineralocorticoid receptor antagonist eplerenone, when compared to chlorthalidone plus potassium chloride, can improve cardiac MRI-derived myocardial perfusion reserve and fibrosis…
- Conditions
- Metabolic Syndrome, Hypertension, Overweight and Obesity
- Trial name
- NCT04519164
- Testing
- Eplerenone, Chlorthalidone with potassium chloride
- Where
- United States
- Volunteers
- 79 people
- Sponsor
- Brigham and Women's Hospital
Obesity, Overweight
A Study of Orforglipron in Adult Participants With Obesity or Overweight and Type 2 Diabetes
This study will investigate the safety and efficacy of once daily oral treatment with orforglipron compared with placebo on body weight in adult participants with obesity or overweight and type 2 diabetes.
- Conditions
- Obesity, Overweight, Type 2 Diabetes
- Trial name
- ATTAIN-2 (NCT05872620)
- Testing
- Orforglipron
- Where
- 136 sites in United States, Argentina and 9 more
- Volunteers
- 1,613 people
- Sponsor
- Eli Lilly and Company